Apokyn (パーキンソン病)：医薬品市場予測及び分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 15
3.1.3 Prognosis 17
3.1.4 Quality of Life 18
3.2 Symptoms 18
4 Disease Management 20
4.1 Overview 20
4.1.1 Diagnosis – The UK Brain Bank Criteria 20
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 21
4.2 Treatment Synopsis 24
4.2.1 Dopaminergic Therapy Classes 24
4.2.2 Treatment of Parkinson’s Disease by Stage 26
4.2.3 Other Treatment Options 29
4.3 Parkinson’s Disease Assessment Scales 29
4.3.1 Unified Parkinson’s Disease Rating Scale (UPDRS) 30
4.3.2 Hoehn and Yahr Clinical Staging 32
4.3.3 Other Clinical Assessments 33
5 Competitive Assessment 34
5.1 Overview 34
5.2 Strategic Competitor Assessment 36
5.3 Dopamine Agonists 38
6 Apokyn (apomorphine) 39
6.1 Overview 39
6.2 Efficacy 41
6.3 Safety 41
6.4 SWOT Analysis 42
6.5 Forecast 42
7 Appendix 44
7.1 Bibliography 44
7.2 Abbreviations 48
7.3 Methodology 51
7.4 Forecasting Methodology 51
7.4.1 Diagnosed Parkinson’s Disease Patients 51
7.4.2 Percent Drug-Treated Patients 52
7.4.3 General Pricing Assumptions 52
7.4.4 Compliance Assumptions 53
7.4.5 Individual Drug Assumptions 54
7.4.6 Generic Erosion 54
7.5 Physicians and Specialists Included in this Study 55
7.6 About the Authors 57
7.6.1 Author 57
7.6.2 Global Head of Healthcare 58
7.7 About GlobalData 59
7.8 Disclaimer 59